ReviewBritish journal of clinical pharmacology2017
Impact of concomitant medications on obstructive sleep apnoea.
Review in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.Diabetes care · 2020Trial
- Effect of lemborexant on insomnia severity, morning alertness, and cognition in participants with insomnia disorder and mild obstructive sleep apnea.Sleep medicine: X · 2026Article
- Sleep Apnea and Cardiovascular Disease: Risks, Mechanisms, Complications, and Management.Reviews in cardiovascular medicine · 2026Review
- Feasibility, Validity and Economic Impact of a Home-Based Sleep Screening Test in the Detection of Sleep-Related Breathing Disorders in Individuals Living With Spinal Cord Injury: A Multi-Method Study and Cost-Minimisation Analysis.Journal of sleep research · 2026Article
- Sleep disturbances in children and adolescents with attention-deficit/hyperactivity disorder: A narrative review.World journal of clinical pediatrics · 2025Review
- "Relationship between obstructive sleep apnea and metabolic syndrome based on the NHANES and Mendelian randomization study".European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Prevalence and impact of comorbid mental disorders in hospitalized patients with obstructive sleep apnea (OSA): a nationwide study using administrative data.The Psychiatric quarterly · 2025Observational
- Hypnotics and infections: disproportionality analysis of the U.S. Food & Drug Administration adverse event reporting system database.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome.Life (Basel, Switzerland) · 2022Article
- Overview: A Framework for the Discussion of Sleep in Multiple Sclerosis.Current sleep medicine reports · 2017Article
- Concomitant medications and obstructive sleep apnoea.British journal of clinical pharmacology · 2017Article
- Drugs and obstructive sleep apnoea.British journal of clinical pharmacology · 2017Article
- Impact of concomitant medications on obstructive sleep apnoea.British journal of clinical pharmacology · 2017Review
- Effectiveness of a lightweight portable auto-CPAP device for the treatment of sleep apnea during high altitude stages of the Dakar Rally: a case report.Sleep science (Sao Paulo, Brazil)Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive sleep apnoea (OSA) is characterized by repeated episodes of apnoea and hypopnoea during sleep. Little is known about the potential impact of therapy drugs on the underlying respiratory disorder. Any influence should be taken into account and appropriate action taken, including drug withdrawal if necessary. Here, we review drugs in terms of their possible impact on OSA; drugs which (1) may worsen OSA; (2) are unlikely to have an impact on OSA; (3) those for which data are scarce or contradictory; and (4) drugs with a potentially improving effect. The level of evidence is ranked according to three grades: A - randomized controlled trials (RCTs) with high statistical power; B - RCTs with lower power, non-randomized comparative studies and observational studies; C - retrospective studies and case reports. Our review enabled us to propose clinical recommendations. Briefly, agents worsening OSA or inducing weight gain, that must be avoided, are clearly identified. Drugs such as 'Z drugs' and sodium oxybate should be used with caution as the literature contains conflicting results. Finally, larger trials are needed to clarify the potential positive impact of certain drugs on OSA. In the meantime, some, such as diuretics or other antihypertensive medications, are helpful in reducing OSA-associated cardiovascular morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.